Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (July 2023)
16 slides from Harrow's investor presentation, Jul 18, 2023
Slide 1: Harrow Investor Presentation July 2023
(a HARROW Your patients. Our purpose. Investor Presentation July 2
Slide 2: Safe Harbor
Safe Harbor ‘his presentation contains express “forward-looking stalements" as defined in the US. Private Secuilies Ligation Reform Act of 1995, You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events, f undettying assump
Slide 3: Why Invest in Harrow
Poised to become a top-tier U.S. ophthalmic pharmaceutical company. Adding new revenue from premium branded and higher margin products, driven by recently acquired branded products. Why Invest in Harrow J @ Transactions with Santen and Novaliq expected to fuel additional growth beginning in 2023 and
Slide 4: Harrow's Eyecare Pharmaceuticals Platform
Harrow’s Eyecare Pharmaceuticals Platform Highly-trusted, integrated pharmaceutical and pharmacy platform consisting of national sales and customer service teams, automated cGMP drug compounding fa s, and an efficient, scalable, and tech-enabled commercialization and distribution platform for prescr
Slide 5: Harrow Revenues and Core Gross Margin
Harrow Revenues and Core Gross Margin (Revenves in Thousands) $88,595 75% 75% 76% $72,476 $51,165 $26,774 $26,103 $19,942 2014 2015 2016 2017 2018 2019 2020 2021 2022 ll Consolidated Revenues ME Core Gross Margin() 1 Core gross maiginis@ non-GAAP measure that excludes rom gros profi all amorzation a
Slide 6: 2023 Financial Guidance
2023 Financial Guidance Calendar Year 2023 o Net revenues of between $135-$143 million o Adjusted EBITDA of between $44-$50 million o Net revenues and Adjusted EBITDA ramping up in 2024 Second Quarter 2023 Guidance o For the three-month period ended June 30, 2023, Harrow expects to record over $31 m
Slide 7: Santen Transaction Summary
Sanien Transaction Summary Acquired most of Santen’s U.S. eyecare portfolio Transaction expected to be financially accretive o US. rights to five branded and one OTC o Following NDA/MA transfers (three to four months), ophthalmology products and Canadian transaction is expected to be immediately acc
Slide 8: Santen Acquisition Portfolio
Santen Acquisition Portfolio Indication /_| Active Pharmaceutical mrtronteen Class Ingredient Nice} 2029 + orphan ONY topical immunomodulator approved for VERKAZIA® Rx Cyclosporine 0.1% exclusivity until 2028 rare disease VKC; cationic emulsion; approved for ages 2° Only on label anti-fungal eye dro
Slide 9: Novaliq Transaction Summary
Novaligq Transaction Summary Recent transaction to acquire North American rights to DED is a large, underserved market in the U.S. FDA-approved VEVYE® from Novaliq GmbH ai . o ~16million are diagnosed. o Patented 0.1% cyclosporine ophthalmic solution . oe a rn ‘ 0 92%remain un- or under-treated due
Slide 10: VEVYE: Broad Label, BID Dosing, Fast Onset, and Mild AEs
VEVYE: Broad Label, BID Dosing, Fast Onset, and Mild AEs a Label Indications Dosing emmy Rcibic al iucies ‘Adverse Events Administration Onset 8% instillation site reactions; 1 7 Vevye® Signs and symptoms of DED BID Schirmer Day 29 temporary decrease in visual acuity 3% ICFS Day 15 & 57 2 Miebo® ‘Si
Slide 11: IHEEZO
IHEEZO (chloroprocaine HCl ophthalmic gel) 34 First approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride. First branded ocular anesthetic approved for the U.S. market in nearly 14 years. IHEEZO Reimbursement: o Permanent J-Code (J2403) - current WAC pricing of $544/unit. o Tran
Slide 12: Fab Five Revitalization Strategy
Fab*Five Revitalization Strategy : ® HLEVED. Nevanac Maxidex sence (nepafenac ophthalmic (nepafenac ophthalmic (dexamethasone aropelely inte pes) Suspension) 0.3% suspension) 0.1% ‘ophthalmi suspension) : a 01% VIGAMOX (maxfioxacin ‘ophthalmic solution) 05% Fab Five History We plan to revitalize the
Slide 13: Harrow U.S. Portfolio
Harrow U.S. 2014 - Present Compounded Proprietary compounded product lines, not FDA approve Cash pay, custom Rx needed DROP LESS GO Less’ ear SIM pe atropine.com QFortisite Pro Form@Ophihalmic Portfolio 2021 - Present THEEZO isnareme toe 8 ILEVRO TobraDex ST (ene eoncarene ein ‘oni saben) eae IOPIDI
Slide 14: Potential Hidden Balance Sheet Value
Potential Hidden Balance Sheet Value Surface Ophthalmics, Melt Pharmaceuticals, and Eton Pharmaceuticals (Nasdaq: ETON) were founded as Harrow subsidiaries and carved-out after hiring management and closing external financings. Harrow owns: o 2million shares of Eton and equity in Surface and Melt (2
Slide 15: Summary of Harrow
Summary of Harrow (Nasdaq: HROW) 2023 Expectations: >50% growth in revenues, stable core gross margins and OpEx/revenue ratio!"). ° Poised to become a Transactions with Santen () || @. top-tier U.S. ophthalmic J) and Novaliq expected to pharmaceutical company. fuel additional growth beginning in 202
Slide 16: Harrow
(a HARROW Your patients. Our purpose. 102 Woodmont Blvd., Suite 610 Nashville, Tennessee 37205 www.Harrow.com Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com Direct: 615-733-4737